AR078046A1 - Proteinas de union a antigeno - Google Patents
Proteinas de union a antigenoInfo
- Publication number
- AR078046A1 AR078046A1 ARP100101812A ARP100101812A AR078046A1 AR 078046 A1 AR078046 A1 AR 078046A1 AR P100101812 A ARP100101812 A AR P100101812A AR P100101812 A ARP100101812 A AR P100101812A AR 078046 A1 AR078046 A1 AR 078046A1
- Authority
- AR
- Argentina
- Prior art keywords
- proteins
- antigen
- antigen binding
- union
- comes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Combinaciones de antagonistas de HGF con antagonistas de VEGF; se proporciona además proteínas de union a antígeno que se unen a HGF, que comprenden un armazon proteico que está unido a uno o más dominios de union a epítopo, en el que la proteína de union a antígeno tiene al menos dos sitios de union a antígeno, al menos uno de los cuales procede de un dominio de union a epítopo y al menos uno de los cuales procede de un dominio VH/VL apareado, a procedimientos de fabricar dichos constructos y a usos de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18188109P | 2009-05-28 | 2009-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR078046A1 true AR078046A1 (es) | 2011-10-12 |
Family
ID=42320696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101812A AR078046A1 (es) | 2009-05-28 | 2010-05-26 | Proteinas de union a antigeno |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120177651A1 (es) |
EP (1) | EP2435478A1 (es) |
JP (1) | JP2012527876A (es) |
AR (1) | AR078046A1 (es) |
CA (1) | CA2763488A1 (es) |
TW (1) | TW201106971A (es) |
UY (1) | UY32663A (es) |
WO (1) | WO2010136482A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2643351A1 (en) * | 2010-11-24 | 2013-10-02 | Glaxo Group Limited | Multispecific antigen binding proteins targeting hgf |
JP2014505698A (ja) | 2011-02-02 | 2014-03-06 | グラクソ グループ リミテッド | 新規抗原結合タンパク質 |
AU2013201422B2 (en) * | 2012-01-23 | 2015-04-09 | Ablynx Nv | Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors |
KR102049990B1 (ko) * | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
PT2992100T (pt) * | 2013-04-29 | 2019-12-16 | Agrosavfe Nv | Composições agroquímicas compreendendo anticorpos que se ligam a esfingolípidos |
EP3004152B1 (en) | 2013-05-31 | 2020-09-30 | Molecular Partners AG | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
KR102236367B1 (ko) * | 2013-07-26 | 2021-04-05 | 삼성전자주식회사 | DARPin을 포함하는 이중 특이 키메라 단백질 |
MX2016013613A (es) * | 2014-04-17 | 2017-02-28 | Teraclón Idf S L | Anticuerpos monoclonales recombinantes vnar neutralizantes del factor de crecimiento del endotelio vascular vegf. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006020258A2 (en) * | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
WO2007109254A2 (en) * | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
EP2535349A1 (en) * | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
-
2010
- 2010-05-26 EP EP10722077A patent/EP2435478A1/en not_active Withdrawn
- 2010-05-26 CA CA2763488A patent/CA2763488A1/en not_active Abandoned
- 2010-05-26 JP JP2012512353A patent/JP2012527876A/ja active Pending
- 2010-05-26 AR ARP100101812A patent/AR078046A1/es not_active Application Discontinuation
- 2010-05-26 UY UY0001032663A patent/UY32663A/es unknown
- 2010-05-26 US US13/322,207 patent/US20120177651A1/en not_active Abandoned
- 2010-05-26 TW TW099116880A patent/TW201106971A/zh unknown
- 2010-05-26 WO PCT/EP2010/057229 patent/WO2010136482A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2010136482A1 (en) | 2010-12-02 |
UY32663A (es) | 2010-12-31 |
TW201106971A (en) | 2011-03-01 |
EP2435478A1 (en) | 2012-04-04 |
US20120177651A1 (en) | 2012-07-12 |
JP2012527876A (ja) | 2012-11-12 |
CA2763488A1 (en) | 2010-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR078046A1 (es) | Proteinas de union a antigeno | |
UY31504A1 (es) | Construcciones de union de antigenos | |
MX2013005847A (es) | Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf. | |
BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
UY32501A (es) | Anticuerpo antagonista específico para el heterodímero alfa4-beta7 | |
ECSP17083779A (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos | |
AR088403A1 (es) | Anticuerpo de union a multiples antigenos estable | |
CY1122978T1 (el) | Αντισωματα εναντι-vla-4 | |
BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
UY33588A (es) | Moleculas de union a vegf | |
DK2681244T3 (da) | Cea-antistoffer | |
BR112016022841A2 (pt) | cadeia j modificada | |
AR106555A1 (es) | Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas | |
EA201201016A1 (ru) | Антидоты антикоагулянтов | |
CL2014001297A1 (es) | Anticuerpo multivalente que tiene al menos dos dominios de unión a receptores para dos diferentes sitios de unión de un receptor diana lrp6; anticuerpo aislado biparatopico que une lrp6; anticuerpo igg biparatópico; secuencia nucleotídica que los codifica; vector; composición farmacéutica que los comprende; y uso para tratar cáncer que exprese lrp6 (div. sol. n°3093-12). | |
BR112012022210A2 (pt) | anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado | |
BR112016011401A2 (pt) | moduladores de aplnr e utilizações dos mesmos | |
AR115320A1 (es) | Anticuerpo multivalente | |
EA201171494A1 (ru) | Миметики белка smac | |
DK2885639T3 (da) | Kompleksspecifikke antistoffer og antistoffragmenter og deres anvendelse | |
BRPI1016204A2 (pt) | proteínas de fusão de anticorpos com sítios de ligação fcrn modificados | |
EA201600141A1 (ru) | Терапевтический слитый белок | |
EA201301090A1 (ru) | Антидоты антикоагулянтов | |
BR112015021964A2 (pt) | Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos | |
BR112015016447A8 (pt) | fragmentos de anticorpos, composições e usos dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |